Mankind Pharma Limited EBIT

The latest EBIT for MANKIND.BO is $31B as of June 2026. That compares with $30B in the prior-year period — up 5.9% year over year. That is below the sector sector average of $2.5T. Investors often review this figure alongside Mankind Pharma Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, MANKIND.BO's EBIT moved from $30B to $31B — a 5.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Mankind Pharma Limited's operating scale or balance-sheet position.

Against its sector companies, MANKIND.BO currently prints $31B for EBIT, while the sector average sits near $2.5T. That is roughly 98.7% below the sector mean. Large gaps often invite a closer look at Mankind Pharma Limited's growth, margins, and balance sheet.

A EBIT figure of $31B for MANKIND.BO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.5T. Explore the charts below for those layers of context.

After noting MANKIND.BO's EBIT ($31B), review year-over-year change from $30B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.